Abbott Lowers Earnings Forecast After $21B Exact Sciences Buy

Why It Matters

The forecast cut highlights short‑term earnings pressure from integration costs, while the acquisition positions Abbott for long‑term growth in high‑margin cancer diagnostics.

Key Takeaways

• Abbott cuts 2026 EPS forecast after $21B Exact acquisition.
• Exact Sciences expected to contribute $3B incremental sales in 2026.
• Q1 sales rise 7.8% to $11.16B, but net income falls 19%.
• Diabetes segment growth missed 11.5% target, slowing overall outlook.
• Shares dropped 4% to $97.58 amid mixed segment performance.

Pulse Analysis

The $21 billion purchase of Exact Sciences gives Abbott a foothold in the rapidly expanding cancer‑diagnostics market. Exact’s Cologuard test, which detects colorectal cancer through stool DNA, is poised for higher utilization as screening guidelines shift the recommended age from 50 to 45 and colonoscopy wait times stretch to nine months. By adding a proven, non‑invasive platform, Abbott can cross‑sell its extensive MedTech distribution network and accelerate development of companion assays for therapy selection and minimal residual disease detection.

Despite the strategic upside, the acquisition immediately pressured Abbott’s earnings outlook. Adjusted EPS for 2026 was trimmed to $5.38‑$5.58, reflecting a $0.20 per‑share dilution and slower‑than‑expected performance in core segments. First‑quarter revenue climbed 7.8% to $11.16 billion, yet net income slipped 19% and diabetes‑care growth lagged behind the 11.5% consensus. The market reacted with a 4% share decline to $97.58, underscoring investor concern that near‑term earnings may be weighed down while integration costs mount.

Looking ahead, Abbott expects Exact to contribute roughly $3 billion of incremental sales in 2026, a target that hinges on expanding Cologuard adoption and launching new oncology panels. Successful FDA clearance of the glucose‑ketone sensor later this year could revive the diabetes franchise and provide a catalyst for earnings recovery. However, the company must harmonize cultures, streamline R&D pipelines, and manage supply‑chain complexities to unlock the full value of the deal. If executed well, the acquisition could position Abbott as a leading integrated player across MedTech and diagnostics.